Related Experiment Video

Updated: Mar 5, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.4K

New drug development in head and neck squamous cell carcinoma: The PI3-K inhibitors

Francesca De Felice1, Teresa Guerrero Urbano2

  • 1Department of Radiotherapy, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy.

Oral Oncology
|March 30, 2017
PubMed

Insights

New phosphatidylinositol 3-kinase (PI3-K) inhibitors are being studied for head and neck squamous cell carcinoma (HNSCC). This review updates clinical trials and discusses challenges for PI3-K inhibitors in HNSCC treatment.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Phosphatidylinositol 3-kinase (PI3-K) pathway deregulation is frequent in head and neck squamous cell carcinoma (HNSCC).
  • PI3-K inhibitors represent a promising therapeutic avenue for HNSCC.

Purpose of the Study:

  • To review recent clinical trials of PI3-K inhibitors in HNSCC.
  • To highlight the challenges associated with PI3-K inhibitor therapy in HNSCC.

Main Methods:

  • Review of published clinical trials involving PI3-K inhibitors (e.g., BKM120, PX-866, BYL719).
  • Focus on trials in patients with locally advanced, recurrent, or metastatic HNSCC.

Main Results:

  • Several PI3-K inhibitors are under investigation in Phase I and II clinical studies.
  • Ongoing research explores the efficacy and safety of these agents in HNSCC.

Conclusions:

  • PI3-K inhibitors show potential in treating advanced HNSCC.
  • Overcoming therapeutic challenges is crucial for successful clinical application.
Keywords:
Head and neck cancerLocally advanced diseasePI3-K inhibitorsRadiotherapyRecurrenceSquamous cellSurvival

More Related Videos

Three-Dimensional 3D Tumor Spheroid Invasion Assay12:19

Three-Dimensional 3D Tumor Spheroid Invasion Assay

Published on: May 1, 2015

59.8K
Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma12:03

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma

Published on: July 25, 2011

20.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
698
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K